Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective...
Guardado en:
Autores principales: | Youlian Zhou, Zhenjiang Zech Xu, Yan He, Yunsheng Yang, Le Liu, Qianyun Lin, Yuqiang Nie, Mingsong Li, Fachao Zhi, Side Liu, Amnon Amir, Antonio González, Anupriya Tripathi, Minhu Chen, Gary D. Wu, Rob Knight, Hongwei Zhou, Ye Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7dbb98bdfa1646aab64644807868380f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: David Ternant, et al.
Publicado: (2021) -
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
por: Sara Salvador-Martín, et al.
Publicado: (2021) -
Eficacia del infliximab en pacientes con síndrome de Behçet portadores de úveo-retinitis grave
por: Merino,Guillermo, et al.
Publicado: (2006) -
Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
por: Labarca S,Cristián, et al.
Publicado: (2003) -
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021)